Dr Reddy's re-launches generic Zenatane capsules in US

Image
Press Trust of India New Delhi
Last Updated : Jun 03 2019 | 8:50 PM IST

Drug firm Dr Reddy's Laboratories said Monday it has re-launched its generic Zenatane capsules in the US market.

The company has re-launched Zenatane (Isotretinoin Capsules, USP) in the strengths of 10 mg, 20 mg, 30 mg and 40 mg, Dr Reddy's said in a statement.

The product is a generic version of Hoffman LaRoche's Accutane capsules, it added.

The product is being launched with an approved Risk Evaluation and Mitigation Strategy (REMS) Program, Dr Reddy's said.

"We're pleased to bring this important product back to market for the customers and patients who will benefit from access to this medicine and who have had witnessed limited supply and options in the market place," Dr Reddy's North America Generics CEO Marc Kikuchi said.

According to IQVIA Health data, the Zenatane capsules 10 mg, 20 mg, 30 mg and 40 mg brand and generic had US sales of approximately USD 525 million MAT for the most recent twelve months ending in March 2019.

Shares of Dr Reddy's Laboratories closed at Rs 2,718.90 on BSE, up 1.54 per cent from the previous close.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 03 2019 | 8:50 PM IST

Next Story